- Get the Story RightJanuary 11, 2018 | Laura C. Michaelis, MD
Dr. Michaelis covers some of her goals and ideas as the new Editor-in-Chief of The Hematologist and discusses the importance of using this medium to share data, important information, and stories of patients we meet along the way, to move forward the field of hematology.
- A Lot of Attention on Aplastic AnemiaJanuary 10, 2018 | Sioban Keel, MD
Dr. Keel looks at a study that reviews the use of eltrombopag in combination with antithymocyte globulin and cyclosporine in refractory severe aplastic anemia treatment-naive patients, among other studies.
- A Pill Instead of a Needle for Cancer-Associated Venous Thromboembolism? YES!January 10, 2018 | Lori-Ann Linkins, MD, MSc(Clin Epi), FRCPC
Dr. Linkins considers oral direct anticoagulants as an attractive alternative to low-molecular-weight heparin injections to treat patients with cancer-associated VTE.
- Acute Deep Vein Thrombosis: Selecting the Right Patient for ThrombolysisJanuary 10, 2018 | Stephan Moll, MD
Dr. Moll discusses the ATTRACT Trial, which demonstrated that catheter-directed pharmacomechanical thrombolysis did not prevent the development of PTS in patients with acute proximal DVT, but increased the risk for major bleeding.
- Best of 2017 in Multiple MyelomaJanuary 10, 2018 | Andrew J. Yee, MD | Noopur Raje, MD
Dr. Raje and Dr. Yee look at the RVD regimen (lenalidomide, bortezomib, and dexamethasone) as standard of care in newly diagnosed multiple myeloma.
- Venetoclax: Shaking CLL Off the TreeJanuary 10, 2018 | Paul Moss, PhD
Dr. Moss covers several trials that have solidified the use of venetoclax as the new backbone within a range of combination therapies that should achieve extremely deep therapeutic responses in CLL.
- A Landmark Year for FDA-Approved Therapies for Acute Myeloid LeukemiaJanuary 09, 2018 | Omar Abdel-Wahab, MD
Dr. Abdel-Wahab reviews the FDA approval in 2017 of four new therapeutic options for treating acute myeloid leukemia patients.
- Clonal Hematopoiesis Can Risk Stratify Patients With Cytopenias and in Cardiovascular DiseaseJanuary 09, 2018 | Joanna Conant, MD | Tracy I. George, MD
Drs. George and Conant review a study that shows that in patients with unexplained cytopenias, the detection of somatic mutations can stratify patients into being at low or high risk for developing myeloid malignancies. CHIP has clinical impact beyond increased risk for developing hematopoietic neoplasms and may have further implications in nonhematologic areas.
- Old Dog, New Tricks: Targeting CD20 in B Cell Non-Hodgkin LymphomasJanuary 09, 2018 | Caron A. Jacobson, MD
Dr. Jacobson looks at two randomized trials that demonstrate a benefit of antibody therapy against CD20 in new contexts in mantle cell lymphoma and follicular lymphoma 20 years after the initial FDA approval of rituximab to treat B cell lymphoma.
- Successes in Gene Therapy: 2017January 09, 2018 | Jonathan Hoggatt, PhD
Dr. Hoggatt covers successes in gene therapy achieved during 2017 and expresses excitement in what's to come for the field.
- The Year's Best in Sickle Cell Disease for 2017January 09, 2018 | Michael DeBaun, MD, MPH
Dr. DeBaun discusses the successful completion of the phase II trial (largest completed randomized controlled trial in SCD) using the anti-P-selectin antibody crizanlizumab for the prevention of acute vaso-occlusive pain events in SCD and two other important discoveries in 2017 for treating SCD.
- Lighting the Path to Personalized Medicine for Hematologic Malignancies: Lessons From an AML Knowledge BankDecember 22, 2017 | Andrew Roberts, MBBS, PhD, FRACP, FRCPA
Dr. Roberts discusses a model known as the AML knowledge bank that outperformed current standard prognostic criteria in predicting individual survival outcomes and could be used as a decision support tool for individual patient treatment recommendations in the effort to bring precision medicine to the forefront.
- Simplifying 6-MP DeliveryDecember 22, 2017 | Luke Maese, DO | Elizabeth Raetz, MD
Dr. Maese and Dr. Raetz review several studies that have defined the scope and magnitude of medication nonadherence in childhood ALL including the fact that one-third of ALL relapses are attributed to 6-MP nonadherence. They stress the need for simplification of 6-MP delivery instructions.